



SUPPLEMENTARY FIG. S2. Prolonged treatment with TRAIL does not significantly affect survival of human embryonic stem cells (hESC) and hiPSC. The hESC and hiPSC were either left untreated (control) or treated with 200 ng/mL of human recombinant TRAIL for 24 or 48 h. **(A)** Induction of apoptosis was determined by staining with an antibody that was specific to cleaved PARP. The percentage of cells positive for cleaved PARP (% apoptotic cells) in the control and TRAIL-treated cells was determined by flow cytometry. Each bar represents the mean of $n=3$ experiments; error bars show \pm SEM. **(B)** Cell death was determined by DNA content analysis by flow cytometry. The subG1 population is gated. Representative histograms of two independent experiments are shown.